Vertex Pharmaceuticals Inc.'s newest cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) has exceeded Wall Street projections for prescriptions and patient starts, the company reported during its third quarter earnings call Oct. 28.
Orkambi, which combines the cystic fibrosis transmembrane conductance regulator (CFTR) gene potentiator Kalydeco (ivacaftor) with the CFTR corrector lumicaftor, obtained FDA approval on July 2 and posted sales of $131m in its first three months on the market ([A#14150702004])
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?